Literature DB >> 16621245

Differential effects of bisphosphonates on breast cancer cell lines.

R Verdijk1, H R Franke, F Wolbers, I Vermes.   

Abstract

Bisphosphonates may induce direct anti-tumor effects in breast cancer cells in vitro. In this study, six bisphosphonates were administered to three breast cancer cell lines. Cell proliferation was measured by quantification of the expression of Cyclin D1 mRNA. Apoptosis was determined by flow cytometry of a DNA fragmentation assay. We demonstrated that bisphosphonates have direct effects on cell proliferation and apoptosis in different breast cancer cell lines. However, not all bisphosphonates act equally on breast cancer cells in vitro. Zoledronate seems to be the most potent of the six bisphosphonates. This in vitro study showed that bisphosphonates possess promising anti-tumor potential.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16621245     DOI: 10.1016/j.canlet.2006.03.011

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  17 in total

Review 1.  Direct antitumour activity of zoledronic acid: preclinical and clinical data.

Authors:  Joaquim Bosch-Barrera; Sofía D Merajver; Javier A Menéndez; Catherine Van Poznak
Journal:  Clin Transl Oncol       Date:  2011-03       Impact factor: 3.405

2.  The miR-21/PTEN/Akt signaling pathway is involved in the anti-tumoral effects of zoledronic acid in human breast cancer cell lines.

Authors:  M Fragni; S A Bonini; P Bettinsoli; S Bodei; D Generali; A Bottini; P F Spano; M Memo; S Sigala
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-02-24       Impact factor: 3.000

3.  Effect of bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of alendronate and zoledronic acid.

Authors:  Trisha F Hue; Steven R Cummings; Jane A Cauley; Douglas C Bauer; Kristine E Ensrud; Elizabeth Barrett-Connor; Dennis M Black
Journal:  JAMA Intern Med       Date:  2014-10       Impact factor: 21.873

4.  Zoledronic acid inhibits aromatase activity and phosphorylation: potential mechanism for additive zoledronic acid and letrozole drug interaction.

Authors:  Amanda J Schech; Brandon E Nemieboka; Angela H Brodie
Journal:  J Steroid Biochem Mol Biol       Date:  2012-06-01       Impact factor: 4.292

Review 5.  Hormesis and medicine.

Authors:  Edward J Calabrese
Journal:  Br J Clin Pharmacol       Date:  2008-06-28       Impact factor: 4.335

6.  Zoledronic acid reverses the epithelial-mesenchymal transition and inhibits self-renewal of breast cancer cells through inactivation of NF-κB.

Authors:  Amanda J Schech; Armina A Kazi; Rabia A Gilani; Angela H Brodie
Journal:  Mol Cancer Ther       Date:  2013-04-25       Impact factor: 6.261

Review 7.  Zoledronic acid: a review of its use in breast cancer.

Authors:  Katherine A Lyseng-Williamson
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 8.  Bone health issues in women with early-stage breast cancer receiving aromatase inhibitors.

Authors:  Adam M Brufsky
Journal:  Curr Oncol Rep       Date:  2008-01       Impact factor: 5.075

9.  Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis.

Authors:  Antonis Valachis; Nikolaos P Polyzos; Robert E Coleman; Michael Gnant; Holger Eidtmann; Adam M Brufsky; Rebecca Aft; Amye J Tevaarwerk; Karen Swenson; Pehr Lind; Davide Mauri
Journal:  Oncologist       Date:  2013-02-12

10.  Zoledronic acid induces apoptosis via stimulating the expressions of ERN1, TLR2, and IRF5 genes in glioma cells.

Authors:  Cigir Biray Avci; Cansu Caliskan Kurt; Burcu Erbaykent Tepedelen; Ozgun Ozalp; Bakiye Goker; Zeynep Mutlu; Yavuz Dodurga; Levent Elmas; Cumhur Gunduz
Journal:  Tumour Biol       Date:  2015-12-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.